Fitabeo Therapeutics appoints Dr Parameswara Rao Vuddanda to lead Technology and Product Development

Dr Parameswara Rao Vuddanda has been appointed as Development Director, to accelerate Technology and Product Development and drive Fitabeo Therapeutics’ quest of delivering innovative medicines.

Edinburgh, United Kingdom; 12th July 2023

Fitabeo Therapeutics, an Edinburgh-based clinical-stage pharmaceutical company, aims to tackle critical healthcare challenges by developing innovative treatments. Fitabeo Therapeutics is delighted to annouce the appointment of Dr Parameshwara Rao (Paramesh) Vuddanda to lead its Technology and Product Development, as Development Director.

Dr Vuddanda has held a variety of technical posts within the pharma industry and brings deep expertise in the development and commercialisation of oral thin films. Dr Vuddanda’s appointment will greatly contribute to accelerating the commercial development of Fitabeo’s portfolio.

“We are delighted to welcome Paramesh to Fitabeo Therapeutics. Paramesh brings a wealth of experience and a fresh approach to technical operations that will play a key role in ensuring we continue to work as effectively as possible to supply medicines that meet patient needs,” said Prof Alex Mullen, Chief Scientific Officer of Fitabeo Therapeutics.




Notes to editors.

For further information, please contact:

Mohini Kochrekar, Communications Manager

[email protected]



About Fitabeo Therapeutics

Fitabeo Therapeutics is a clinical-stage pharmaceutical company that develops and commercialises innovative medicines focusing on indications where existing treatments are inadequate for the target population to provide better health outcomes. It deploys ground-breaking technologies to create medications that enable decentralised patient care and provide significant healthcare savings.